Galliprant is a drug owned by ELANCO US INC. It is protected by 5 US drug patents filed from 2021 to 2035. Out of these, 4 patents are active and 1 patent has expired. Details of Galliprant’s patents and their expiration are given below.
| Drug Patent Number | Drug Patent Expiry | Status |
|---|---|---|
 | ||
| US11369621 | 05 Mar, 2035 | Active |
| US7960407 | 10 Jul, 2029 | Active |
| US6710054 | 15 Oct, 2021 | Expired |
Exclusivity Information
Galliprant holds 1 exclusivity out of which 1 has expired. Details of Galliprant's exclusivity codes and their expiration dates are given below.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| NCE | Mar 20, 2021 |
Galliprant Petitions
Details of Galliprant's suitability petitions are listed below.
| Petitioner | Action | Date of Action | Description |
|---|---|---|---|
 | |||
| Aurora Pharmaceutical, Inc. | Approved | NA | |
About Galliprant
Galliprant is a drug
owned by ELANCO US INC.
Galliprant uses
Grapiprant as the active
ingredient.
Active Ingredient:
Galliprant uses
Grapiprant as the active ingredient.
Check out other Drugs and Companies using
Grapiprant ingredient.